A venture capital firm with multiple offices in the USA has assets under management of $1.6 billion. Since inception, the firm has raised five investment funds. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity.
The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.
The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Venture Capital Firm Invests Up to $20M in USA-Based Novel Therapeutics and Medical Devices Companies
14 JulSubscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 
Leave a Reply